Skip to content

Checked

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619 on ClinicalTrials.gov

Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.

Status
Recruiting
Phase
Phase 2
Interventional
Planned enrollment
40
Participants, all sites
U.S. sites
11
In 10 states

Study details

Conditions
Lupus Nephritis
Sponsor
Hoffmann-La Roche (Industry)
Ages
5 to 17 years
Sex
All
Healthy volunteers
Not accepted
Start
05/12/2022
Primary completion (expected)
06/15/2028
Last updated by sponsor
10/06/2026

Full eligibility rules, contacts and site names: NCT05039619 on ClinicalTrials.gov

Where the study has sites

Cities with at least one listed U.S. site. Some sites may not be enrolling yet.

  • California: Loma Linda, San Francisco
  • Colorado: Aurora
  • Georgia: Atlanta
  • Indiana: Indianapolis
  • Louisiana: Shreveport
  • New Jersey: Hackensack
  • New York: Queens
  • Ohio: Cincinnati
  • Pennsylvania: Philadelphia
  • Texas: El Paso

More studies on the same topic

Frequently asked questions

What does recruiting mean?
Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
How do I join a clinical trial?
Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.

Source: ClinicalTrials.gov, National Library of Medicine · Last updated 10/06/2026